Patent: 9,555,112
✉ Email this page to a colleague
Summary for Patent: 9,555,112
Title: | Monoclonal antibodies against HER2 epitope and methods of use thereof |
Abstract: | This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications. |
Inventor(s): | Bodyak; Natalya D. (Brookline, MA), DeVit; Michael J. (Sudbury, MA), Krauland; Eric M. (Lebanon, NH), Lowinger; Timothy B. (Carlisle, MA), Park; Peter U. (Somerville, MA), Prinz; Bianka (Lebanon, NH), Yurkovetskiy; Aleksandr V. (Littleton, MA) |
Assignee: | Mersana Therapeutics, Inc. (Cambridge, MA) |
Application Number: | 14/742,947 |
Patent Claims: | see list of patent claims |
Details for Patent 9,555,112
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2034-06-18 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2034-06-18 |
Genentech, Inc. | PERJETA | pertuzumab | Injection | 125409 | 06/08/2012 | ⤷ Try a Trial | 2034-06-18 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2034-06-18 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |